OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Medical Economics is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression	152
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction Act	56
Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): the influence of differing European health care payment systems on the potential fin	51
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	51
Economic value of intra-articular knee OA therapies: a U.S. perspective	50
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2– advanced breast cancer: a Medicare perspective	46
Calculating cost per event avoided using a composite number needed to treat	35
Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia	29
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment	29
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphom	28
Correction	28
Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening	28
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	27
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	27
Projected clinical and economic benefits of improved patent foramen ovale testing among cryptogenic stroke patients in the United States	27
Response to “methodological opacity in sword health digital pelvic health”	25
Impact of high body mass index on health state utilities: a time trade-off study in the general population of Japan	23
Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective	23
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych	23
The economic burden of systemic lupus erythematosus in Taiwan	22
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	21
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	21
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	21